Table 1.
Baseline characteristics of the experimental group patients according to the CYP2C19*2 and *3 genotype
| CYP2C19 | CYP2C19 | CYP2C19 | P (value) | |
|---|---|---|---|---|
| *1/*1 | *1/*2, *1/*3 | *2/*2, *2/*3, *3/*3 | ||
| (n=38) | (n=53) | (n=10) | ||
| Age, years | 69.71±13.44 | 69.62±11.20 | 64.30±15.38 | 0.440 |
| Male (%) | 8 (21.1%) | 17 (32.1%) | 3 (30.0%) | 0.512 |
| BMIa, Kg/m2 | 23.18±7.89 | 24.52±4.74 | 22.54±9.48 | 0.560 |
| Smoking status | 0.125 | |||
| Non-smoker | 30 (78.9%) | 48 (90.6%) | 10 (100%) | |
| Ex-smoker | 4 (10.5%) | 3 (5.7%) | 0 (0%) | |
| Habitual smoker | 4 (10.5%) | 2 (3.8%) | 0 (0%) | |
| Hypertension | 24 (63.2%) | 29 (54.7%) | 4 (40.0%) | 0.402 |
| Hyperlipidemia | 4 (10.5%) | 10 (18.9%) | 3 (30.0%) | 0.297 |
| Diabetes mellitus | 13 (34.2%) | 22 (41.5%) | 4 (40.0%) | 0.782 |
| ACEIb | 19 (50.0%) | 20 (37.7%) | 4 (40.0%) | 0.477 |
| ARBc | 28 (73.7%) | 39 (73.6%) | 7 (70.0%) | 0.935 |
| Calcium-channel blocker | 25 (65.8%) | 36 (67.9%) | 7 (70.0%) | 0.982 |
| β-receptor blocker | 30 (78.9%) | 46 (86.8%) | 8 (80.0%) | 0.579 |
| Statins | 35 (92.1%) | 51 (96.2%) | 10 (100.0%) | 0.546 |
| Proton-pump inhibitor | 22 (57.9%) | 30 (56.6%) | 4 (40.0%) | 0.538 |
| Aspirin | 10 (26.3%) | 13 (24.5%) | 3 (30.0%) | 0.941 |
a
- body mass index;
b
- angiotensin-converting enzyme inhibitor;
c
- angiotensin receptor blocker
Multivariate logistic regression analysis was performed to exclude other potential confounding factors between genotypes and the efficacy of clopidogrel treatment.
Demographic characteristics and baseline data between three genotypes of CYP2C19 groups were well balanced